Share

Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows

Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on...
Share

Increase in Pappalysin Levels Could Promote IGF-1 Bioavailability in Children with Prader-Willi Syndrome

The increase in free insulin-like growth factor (IGF)-I levels in prepubertal children with Prader-Willi Syndrome (PWS) treated with exogenous growth hormone (GH) could be caused by increased pregnancy-associated plasma protein A (PAPP-A, PAPP-A2) levels and a reduction in stanniocalcins (STC-1, STC-2), according to a study recently published in The Journal of Clinical Endocrinology & Metabolism....
Share

Pharma Fridays – February 16, 2024

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Medicare Coverage Significantly Expanded for the Eversense E3 CGM System On February 12, Ascensia Diabetes Care, announced that Medicare has significantly expanded access to the Eversense E3 CGM System with the implementation of Local Coverage Determinations providing access to implantable CGM...
Share

Staying Curious: How Felix Beuschlein, MD, Has Advanced Adrenal Tumor Care Through Transatlantic Collaboration 

Beuschlein staircase Honored by both the Endocrine Society and the European Society of Endocrinology with the 2024 Transatlantic Alliance Award, Felix Beuschlein, MD, has made significant contributions to endocrine research on both sides of the Atlantic, from Michigan to Switzerland! Endocrine News speaks with Beuschlein about what this award means to him, conducting pioneering research on two...
Share

Pharma Friday – February 9

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia Last month, Spruce Biosciences, announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH). Spruce Biosciences is...
Share

Introducing EndoForum, the Endocrine Society’s Rebranded Online Community

After initially launching in 2022 and growing into a thriving community in 2023, the Endocrine Society’s online community in DocMatter is ready to step out into the spotlight with a brand-new name: EndoForum!  Why change the name? EndoForum is more than just the platform it’s on; it is a vibrant and active community of more than 16,000 Endocrine Society...
Share

Endocrine Society Journals Remain Premier Venue for Publishing Endocrine Research

Hammes-ENDO 2022RESIZED Year after year, I am continually impressed with the quality and quantity of research that is published in the Society’s suite of scientific journals. As the former co-editor-in-chief, with Andrea Gore, of the Society’s basic science flagship journal Endocrinology, and editor-in-chief of the Society’s other previous basic science journal, Molecular Endocrinology, I was privileged to...